Skip to main content
. Author manuscript; available in PMC: 2014 May 21.
Published in final edited form as: Cancer Chemother Pharmacol. 2013 Mar 9;71(5):1241–1246. doi: 10.1007/s00280-013-2118-9

Table 3.

Number of patients experiencing selected adverse events by dose level

Dose level 1 (n = 18)
Dose level 2 (n = 3)
AE grade
AE grade
1 2 3 4 5 1 2 3 4
Non-hematologic AE
Elevated alkaline phosphatase 3 2
Allergic reaction 1
Elevated ALT 4 1
Anorexia 1 1
Elevated AST 7 1 1
Dehydration 1
Diarrhea 2 7 3 1 1
Dry skin 3
Dyspnea 3 1
Edema 5 2 1
Fatigue 11 3 2
Hand–foot skin reaction 1 1 1
Headache 3 1
Hypercholesterolemia 4
Hyperglycemia 9 4 1 1 1
Hypertension 1 4 1 1
Hypertriglyceridemia 5 1 1
Hypoalbuminemia 1 1
Hypocalcemia 9 1 2 3
Hypokalemia 3 1
Hypomagnesemia 6 1
Hyponatremia 3 1
Hypophosphatemia 3 3 3 1 1
Infection 2
Stomatitis 7 1
Nausea 9 1 1 1
Neuropathy 3
Mouth pain 3 1
Bowel perforation 1
Pneumonitis 1
Pruritus 5
Rash 8 5 2 1 1
Voice changes 2
Vomiting 6 1 2
Weight loss 3
Hematologic AE
Anemia 13 2 2 1
Leukopenia 6 4 1 2 1
Lymphopenia 2 1
Neutropenia 4 5 1 2
Thrombocytopenia 11 3 2 1 1